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Abstract: Problem statement: Osteoarthritis is an inflammatory joint disease associated with loss of 
cartilage matrix. There is suggestive evidence that the intake of polydextrose fiber has anti-inflammatory 
activity.  It  was  reasoned  that  polydextrose  may  have  a  positive  influence  on  canine  osteoarthritis. 
Approach: A double-blind, placebo-controlled trial with privately owned dogs was carried out to assess 
the  efficacy  of  STA-LITE®  polydextrose  in  the  treatment  of  osteoarthritis.  With  the  use  of  a 
questionnaire,  five  clinical  signs  were  evaluated  by  the  owners.  For  a  period  of  8  weeks,  the  dogs 
received a complete dry food without or with 3% polydextrose. There were 16 control and 19 test dogs. 
Results: The baseline values of clinical scores for swelling of joints, stiffness and lameness indicated 
that the severity of osteoarthritis was much less in test dogs than in the controls. The initial scores for 
activity and pain were similar in two groups. Comparing the changes in clinical scores over time 
between control and test dogs would be biased by the difference in baseline severity of osteoarthritis. 
On strict terms, a maximum number of pairs of matched control and test dogs was formed for each 
clinical sign. It was found that all five clinical signs showed more group-mean improvement in the 
dogs fed the diet containing polydextrose than in those given the control diet. The difference between 
the pooled group-mean changes of the control and test dogs was statistically significant. As an overall 
index of the improvement of osteoarthritis, the sum of changes for the five clinical variables was 
calculated.  Polydextrose  was  found  to  induce  a  marked  improvement  of  osteoarthritis:  The 
polydextrose-mediated  increase  in  the  osteoarthritis  improvement  index  was  57%.  Conclusion: 
Polydextrose  can  be  considered  safe  and  it  is  suggested  that  a  dose  of  3%  in  a  dry  food  can  be 
beneficial for dogs with osteoarthritis. 
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INTRODUCTION 
 
  In dogs, osteoarthritis is a common joint disease 
with  symptoms  such  as  chronic  pain,  lameness  and 
decreased  mobility  (Henrotin  et  al.,  2005). 
Osteoarthritis  is  characterized  by  loss  of  cartilage 
matrix  associated  with  a  release  of  pro-inflammatory 
cytokines (Henrotin et al., 2005). It is not possible to 
cure osteoarthritis, implying that management aims at 
the  relief  of  pain  through  reduction  of  inflammatory 
reactions and further breakdown of cartilage. Treatment 
generally  consists  of  the  use  of  Non-Steroidal  Anti-
Inflammatory  Drugs  (NSAIDS)  to  decrease 
inflammation  and  consequently  pain.  However,  side 
effects such as vomiting and diarrhea may occur (Innes 
et  al.,  2003).  As  an  alternative  to  NSAIDS,  canine 
osteoarthritis  may  be  managed  by  nutraceuticals  that 
are  administered  as  supplements  or  as  ingredients  of 
industrially produced dog foods. The efficacy of fish oil 
(Roush et al., 2010a), gelatin hydrolysate (Beynen et 
al.,  2010)  and  beta-1,3/1,6-glucans  (Beynen  and 
Legerstee, 2010) has been demonstrated in double-blind, 
placebo-controlled  dog  trials.  However,  for  optimum 
management of canine osteoarthritis, further research on 
potential functional ingredients remains necessary.  
  STA-LITE®  polydextrose  is  a  very  pure  fiber 
derived  from  dextrose.  It  is  a  well-tolerated  soluble 
fiber with prebiotic properties, low glycemic response 
and low energy value (Auerbach et al., 2007; Flood et 
al., 2004; Knapp et al., 2008; Jie et al., 2000). STA-
LITE® polydextrose is frequently used to increase the 
fiber content, provide texture, replace sugar and reduce 
calories in foods for human consumption (Cho, 2009). 
Research  has  shown  that  polydextrose  may  have 
specific biological effects, including anti-inflammatory 
activity.  In  rats  fed  a  diet  containing  2%  of American J. Animal & Vet. Sci., 6 (3): 93-99, 2011 
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polydextrose, a significant increase in the concentration 
of IgA in the lumen of the caecum has been observed 
(Peuranen  et  al.,  2004).  In  pigs  fed  a  diet  with  2% 
added polydextrose, the expression of cyclo-oxygenase-
2 (COX-2) in the mucosa of the distal small intestine 
was  found  to  be  significantly  decreased  (Fava  et  al., 
2007).  In  an  experimental  rat  model  of  colitis, 
polydextrose  had  an  anti-inflammatory  effect  that 
reduced  myeloperoxidase  activity,  counteracted 
glutathione content and promoted reduction in lesions 
(Witaicenis  et  al.,  2010).  The  observed  effects  of 
polydextrose on IgA, myeloperoxidase, glutathione and 
COX-2  point  at  anti-inflammatory  activity.  Thus,  it 
could  be  suggested  that  polydextrose  may  have  a 
beneficial influence on canine osteoarthritis.  
  In the present study, the efficacy of a preparation 
of polydextrose in the treatment of canine osteoarthritis 
has  been  evaluated.  In  a  double-blind,  placebo-
controlled trial, privately owned dogs were used and the 
clinical  signs  were  evaluated  by  the  owners.  For  a 
period  of  8  weeks,  the  test  dogs  daily  received  a 
complete dry food without or with 3% polydextrose. 
 
MATERIALS AND METHODS 
 
Animals:  Dogs  with  signs  of  osteoarthritis  were 
recruited  through  breed  associations.  The  (potential) 
participants  were  informed  about  the  purpose  and 
design  of  the  trial  and  had  to  sign  a  statement  on 
informed  consent.  Fifty  three  dogs  were  subjected  to 
either the placebo or test group. Thirteen dogs did not 
finish the trial and the trial questionnaires for another 
five dogs were not complete so that the data for 35 dogs 
(16 dogs in the control group and 19 dogs in the test 
group) were available for analysis. Table 1 shows the 
characteristics  of  the  dogs  as  based  on  the  intake 
questionnaire  completed  by  the  owners.  There  was  a 
wide  variety  of  dog  breeds;  there  were  Labrador 
Retrievers (n = 4), Swiss white Shepherds (n = 4), St 
Bernard dogs (n = 3), Border Collies (n = 3), Shar Pei 
dogs  (n  =  3),  Golden  Retrievers  (n  =  2),  Berner 
Mountain dogs (n = 2), Dutch Partridge dogs (n = 2), 
cross breeds (n = 4) and others (n = 8).  
 
Table 1: General characteristics of the dogs  
  Placebo group  Polydextrose 
Characteristic   (n = 16)  (n = 19) 
Osteoarthritis diagnosed by  16/0  16/3 
veterinarian, yes/no  
Mean age, years (range)  8.9 (5-13)  8.5 (1-12) 
Mean body weight, kg (range)  36.8 (16-75)   31.1 (10-60)  
Gender, female/male/castrated  3/3/10  4/8/7 
Use of analgetics, yes/no  5/11  8/11 
Use of supplements, yes /no  8/8 8/11 
  The  analgetics  used  were  as  follows:  Cortaphen 
forte (n = 4), Rimadyl (n = 3), Carprofen (n = 2) and 
others (n = 4). In 16 dogs various supplements  were 
used. The owners were instructed to continue as usual 
with the administration of analgetic and/or supplement 
during  the  course  of  the  trial.  If  no  analgetic  or 
supplement was used, this was maintained throughout 
the experiment.  
 
Experimental  design:  Recruitment  of  the  dogs, 
keeping  contact  with  the  dog  owners,  supplying  of 
food,  data  collection  and  general  coordination  of  the 
trial was done by LDJ and MS who were blinded to 
treatment  modality.  In  the  intake  questionnaire,  the 
owners  indicated  the  severity  of  osteoarthritis  as 
described below for the trial questionnaire. The eligible 
dogs were allocated to either the placebo or test group 
by  DHJS,  who  kept  the  treatment  code  closed  until 
statistical analysis of the data. The allocation was done 
so that the distribution of osteoarthritis severity would 
be similar for the control and test dogs. 
   All dogs were fed on the same complete dry food 
(Carocroc  Chicken  and  Rice  23/12,  Vobra  Special 
Petfoods  BV,  Veghel,  The  Netherlands),  which  was 
supplied  in  15-kg,  blank  packaging.  The  test  food 
contained  3%  of  polydextrose  (STA-LITE® 
polydextrose, Tate and Lyle, France). The polydextrose 
was added prior to extrusion to the ingredient mixture of 
the control food at the expense of the corn component. 
Testing with healthy dogs had indicated that an inclusion 
level of 3% polydextrose does not negatively affect feces 
consistency (Vasupen et al., 2011). 
  The foods were sent by courier to the dog owners. 
The trial lasted 10 weeks. The first week served as a 
baseline.  During  the  second  week  the  dogs  were 
gradually  transferred  from  their  habitual  diet  to  the 
food  supplied.  During  the  third  week  only  the  food 
supplied was fed, which was continued for another 8 
weeks.  
 
Trial questionnaire: The trial questionnaire was in the 
form  of  a  booklet,  which  also  provided  instructions, 
including  a  completed  example  of  a  question  in  the 
format used. The severity of the signs of osteoarthritis 
was scored by the owners by marking with a cross a 10-
cm, horizontal line. The line was without any unit, but 
functioned  as  a  scale  in  combination  with  the 
description.  The  signs  to  be  scored  by  owners  were: 
activity (vitality), swelling of joint, stiffness, lameness, 
pain. Body condition was also scored. The signs were 
scored on day 0 (start) and weekly afterwards. American J. Animal & Vet. Sci., 6 (3): 93-99, 2011 
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  To  aid  in  scoring  the  signs,  the  following 
descriptions  were  given.  Activity  (vitality).  “How 
active  and  vital  is  your  dog? Is  your  dog  capable  of 
playing?  Does  your  dog  reach  the  door  earlier  than 
you? Is your dog excited when you are taking her/him 
somewhere?” The scale ran from “Not active” (extreme 
left) to “Very active” (extreme right). Swelling of joint. 
“Does  your  dog  have  swelling  on  the  site  of 
osteoarthritis?  Around  the  joint  with  diagnosed 
osteoarthritis, there may be swelling of either a tough or 
soft  nature”.  The  scale  ran  from  “Marked  swelling” 
(extreme  left)  to  “No  swelling”  (extreme  right). 
Stiffness. “How stiff is your dog? Does your dog easily 
get out of its basket in the morning or does it take time 
to get started when going for a walk?” The scale ran 
from “Very stiff” (extreme left) to “Smooth” (extreme 
right). Lameness. “Is your dog lame or does it not use 
one leg at all? Watch your dog carefully to ascertain 
whether  or  not  there  is  a  change  of  the  degree  of 
lameness during the trial”. The scale ran from “Very 
lame”  (extreme  left)  to  “Not  lame”  (extreme  right). 
Pain. “Does the osteoarthritis cause pain in your dog? 
Does your dog growl or scream when she/he gets up or 
makes a wrong movement. Does your dog indicate pain 
or does she/her try to bite you when touching certain 
joints”. The  scale  ran  from  “Usually  an  expression  of 
pain”  (extreme  left)  to  “Never  an  expression  of  pain” 
(extreme  right).  Body  condition.“What  is  the  body 
condition of your dog? In an obese dog, the ribs are not 
visible  and  are  covered  by  a  layer  of  fat  tissue.  In 
addition, the belly is not slimmer than the chest and thus 
shows no waist. A dog with normal body condition has 
ribs that are just visible and shows a waist. A skinny dog 
has pronounced ribs”. The scale ran from “Very skinny” 
(extreme left) to “Very fat” (extreme right). 
 
Data analysis: The marked scales were transferred into 
values  by  using  the  distance,  expressed  in  mm,  of  the 
crosses  from  the  left  side  (=  0  mm).  To  calculate  the 
baselines, the values for day 0 and week 1 were averaged 
per variable per dog. To calculate the final values, those 
for weeks 8, 9 and 10 were averaged. For each dog and 
each variable, the change over time was calculated. The 
data  are  presented  without  units.  To  identify  treatment 
effects,  the  changes  over  time  for  the  placebo  and  test 
group were subjected to the Student’s t test with two-tailed 
P<0.05 as criterion of statistical significance. 
  The data were not only analysed for all animals in 
the control and test group, but also for the maximum 
number of matched control and test animals for each 
clinical sign. The baseline scores for the clinical signs 
of  osteoarthritis  were  generally  higher  for  the  test 
animals, indicating less severity of osteoarthritis. This 
causes  bias  when  comparing  the  changes  over  time 
within the two  groups. The bias  would be associated 
with the phenomenon of regression to the mean and that 
of  baseline-dependent  sensitivity  to  improvement. 
Animals with less severe signs of disease generally are 
less  sensitive  to  treatment.  To  solve  the  problem  of 
bias, for each clinical sign control and test animals were 
matched  so  that  baseline  values  were  similar.  The 
matching was done by DHJS prior to data analysis and 
without  consideration  of  the  final  values.  The  terms 
were that the two baseline values within a pair would 
not differ numerically by three and that for each clinical 
sign  a  maximum  number  of  pairs  had  to  be  formed. 
Then again for each dog and each variable the change 
over  time  was  calculated  and  subjected  to  statistical 
analysis  as  indicated  above.  In  addition,  the  group-
mean changes over time for the five clinical signs were 
added up to arrive at an overall index of improvement 
of osteoarthritis. The index was calculated for both the 
control and test dogs.  
 
RESULTS 
 
  Table  1  shows  that  the  general  characteristics  of 
the  placebo  and  test  group  were  similar.  The  intake 
values for the clinical signs of osteoarthritis (data not 
shown)  changed  erratically  over  time  towards  the 
beginning of the trial. As a result, the baseline values 
for  the  clinical  signs  of  osteoarthritis  were  not 
comparable for the test and placebo group (Table 2). 
The test animals had higher scores for swelling of joint, 
stiffness  and  lameness.  In  particular,  the  difference 
between control and test animals was considerable for 
the  severity  of  lameness.  The  control  dogs  had  an 
average  score  of  49.9,  whereas  the  score  for  the  test 
animals  was  72.1;  this  difference  was  highly 
statistically significant (p = 0.005). The higher score for 
swelling  also  reached  statistical  significance  (p  = 
0.036). The scores for activity and pain were similar for 
the two groups.  
  Table 2 documents the data for the total groups of 
control and test dogs. When compared to the baseline 
values,  the  final  values  in  the  control  dogs  for  all 
clinical  signs,  except  for  pain,  showed  a  significant 
increase. In the dogs fed polydextrose, there only was 
a significant change in the signs of stiffness. When the 
changes over time of the two groups were compared, 
there  were  no  statistically  significant  differences 
(Table 2). Apart from the pain variable, the group-mean 
increases were greater in the control animals.  American J. Animal & Vet. Sci., 6 (3): 93-99, 2011 
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Table 2: Group-mean baseline values and changes over time in the osteoarthritic signs (improvement is indicated by a + sign) for the total groups  
  Placebo (n = 16)    Polydextrose (n = 19)    
  -----------------------------------------  -------------------------------------  P value for difference 
Variable  Baseline  Change   Baseline  Change  in change 
Activity   50.8  +9.4  54.8  +4.6  0.287 
Swelling  73.4  + 4.2  83.2  +1.8  0.059 
Stiffness  38.9  +12.3  49.2  +9.8  0.729 
Lameness  49.9  +9.5  72.1  +3.7  0.446 
Pain  74.3  +1.9  72.8  +3.1  0.664 
  
Table 3: Group-mean baseline values and changes over time in the osteoarthritic signs (improvement is indicated by a + sign) for the matched groups  
    Placebo     Polydextrose     
    -------------------------------------  --------------------------------------  P value for  
Variable  No. of pairs  Baseline  Change   Baseline  Change   difference in change 
Activity  9  51.7  +8.6  52.4  +13.3  0.475 
Swelling  10  76.2  +3.0  76.9  +3.4  0.558 
Stiffness  10  38.0  +14.0  38.1  +17.0  0.583 
Lameness  8  60.9  +1.5  62.6  +6.3  0.332 
Pain  12  73.5  +0.5  73.7  +3.3  0.252 
 
 
 
Fig. 1: Effect  of  polydextrose  on  clinical  signs  of 
osteoarthritis in matched control and test dogs. 
The  bars  represent  the  magnitude  of 
improvement of clinical signs. The improvement 
was  calculated  as  the  difference  between  final 
and initial scores on a 0 (severe signs) to 100 (no 
signs)  scale.  A  =  activity;  Sw  =  swelling  of 
joints; St = stiffness; L = lameness; P = pain; I 
(index) = improvement of the five clinical signs 
combined.  The  group-mean  changes  were 
pooled  for  the  five  clinical  signs  and  the 
difference  between  control  and  test  dogs  was 
found to be statistically significant (p = 0.018). 
 
  The data obtained after matching control and test 
animals  are  presented  in  Table  3.  When  the  changes 
over time of the two groups were compared for each 
clinical  sign,  there  were  no  statistically  significant 
differences (Table 3). The group-mean increases for all 
five clinical signs were greater in the dogs fed the diet 
containing polydextrose (Table 3), which is illustrated 
by  Fig.  1.  The  difference  between  the  pooled  group-
mean  changes  for  the  control  and  test  dogs  was 
statistically significant (p = 0.018).  
   The changes over time for the five clinical signs 
were added up for each group to arrive at an overall 
index  of  improvement  of  osteoarthritis.  The 
improvement index was 27.6 for the placebo group and 
43.3 for the test group (Fig. 1). The extra improvement 
caused by the ingestion of polydextrose was 57%.  
 
DISCUSSION 
 
  An evidence-based application of polydextrose in 
the  treatment  of  canine  osteoarthritis  requires  proven 
efficacy  in  double-blind,  placebo-controlled  clinical 
trials. After matching the control and test animals with 
regard to baseline scores for the clinical signs, the dogs 
fed  the  diet  with  polydextrose  showed  greater 
numerical  improvement  as  to  the  scores  of  activity, 
swelling,  stiffness,  lameness  and  pain,  but  the 
differences between the control and test treatment did 
not  reach  statistical  significance.  The  systematic, 
positive effects of polydextrose on osteoarthritic signs 
resulted  in  a  clear  improvement  of  the  osteoarthritis 
index. Possibly, the lack of statistical significance of the 
polydextrose effects is caused by insufficient statistical 
power in combination with placebo effects rather than 
by an inefficacy of the supplement. The double-blind 
nature of the trial excluded any observer bias, but it is 
well-known that placebo effects occur in double-blind 
studies  on  canine  osteoarthritis  (Dobenecker  et  al., 
2002; Gingerich and Strobel, 2003; Innes et al., 2003; 
Pollard et al., 2006). Likewise, in this study the clinical 
signs of the control animals were improved during the 
course of the study as observed by the owners.  
  This  study  does  not  provide  absolute  proof  that 
polydextrose feeding has a beneficial effect on canine 
osteoarthritis.  The  baseline  severity  of  osteoarthritis 
was less for the test animals than for the control dogs. It 
may  be  expected  that  the  test  animals  were  less American J. Animal & Vet. Sci., 6 (3): 93-99, 2011 
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sensitive to improvement of the clinical signs so that an 
effect  of  polydextrose,  if  any,  could  not  be 
demonstrated. Indeed, the data for the total groups show 
less improvement in the test animals than in the control 
dogs. In other words, the placebo effect may have been 
greater  than  the  polydextrose  effect.  This  is 
substantiated by analyzing the data after matching. For 
the  control  and  test  dogs  matched  with  regard  to 
baseline scores, the group-mean changes were greater 
in  the  polydextrose  group  than  in  the  control  group 
(Fig.  1).  However,  even  after  matching  the 
polydextrose effects on the individual scores did not 
reach  statistical  significance.  This  may  relate  to 
insufficient  statistical  power  because  of  the  small 
sample  size.  When  the  group-mean  changes  were 
pooled  for  the  five  clinical  signs,  the  difference 
between  control  and  test  dogs  was  found  to  be 
statistically  significant.  It  should  be  noted  that  the 
posterior matching procedure may be criticized as it 
could have introduced allocation bias. Clearly, further 
clinical trials are required for definite proof that the 
feeding of polydextrose relieves canine osteoarthritis.  
  In  addition  to  proven  efficacy,  the  use  of 
polydextrose  in  the  treatment  of  canine  osteoarthritis 
should have a scientific basis. It should be possible to 
explain in molecular terms how it inhibits inflammation 
and/or  how  it  inhibits  breakdown  of  the  cartilage 
matrix. In vitro (Makivuokko et al., 2005) and in vivo 
research in pigs (Fava et al., 2007) has demonstrated 
that  polydextrose  reduces  the  expression  of  COX-2. 
This  effect  may  lead  to  reduced  production  of 
prostaglandin E2 (PG-E2) which is responsible for the 
clinical  signs  like  pain  and  swelling  of  joints.  There 
appears to be similarity between polydextrose and fish 
oil. The intake of fish oil reduces the severity of canine 
osteoarthritis  (Roush  et  al.,  2010a;  2010b)  and  it 
inhibits both the activity of COX-2 and the breakdown 
of  cartilage  proteoglycans  (Curtis  et  al.,  2000).  It  is 
difficult to see that intake of polydextrose inhibits the 
degradation of cartilage. For rats fed polydextrose, an 
increase in the area of ileal mucosa with cells producing 
interleukin-1 (IL-1) has been reported (Peuranen et al., 
2004).  IL-1  stimulates  the  production  of  Matrix 
Metalloproteinase-3  (MMP-3)  by  chondrocytes 
(O’Connor and Fitzgerald, 1994) which is involved 
in  the  degradation  of  collagen  molecules  in  the 
cartilage matrix.  
  In the control dogs, group-mean baseline and final 
scores for body condition were 46.7 and 47.1. During 
the course of the study, the group-mean scores of the 
test  dogs  increased  from  51.4  to  64.7.  Although  the 
increase was not statistically significant (p = 0.235), it 
might  point  at  some  weight  gain.  In  retrospect,  it  is 
unfortunate  that  the  dogs  in  this  study  were  not 
weighed. A general feeding schedule was supplied, but 
the amount of food provided was determined by the dog 
owners  and  thus  was  not  controlled.  It  could  be 
speculated that the relief of osteoarthritis as induced by 
polydextrose had improved wellbeing of the dogs and 
thereby stimulated appetite. Weight loss in obese dogs 
is associated with a decrease in the severity of canine 
osteoarthritis (Impellizeri et al., 2000; Mlacnik et al., 
2006; Marshall et al., 2010). The test dogs  were  not 
obese  as  is  indicated  by  the  scores  for  body 
condition.  Nevertheless,  it  is  possible  that  the 
positive  effect  of  polydextrose  on  osteoarthritis  is 
somewhat  underestimated  because  of  the 
simultaneous tendency towards slight weight gain. It 
should  be  noted  that  the  quantitative  amount  of 
weight gain of the test dogs, if any, is unknown and 
so is the relationship between weight gain, duration 
of overweight and the severity of osteoarthritis. 
 
CONCLUSION 
 
  This  study  does  not  provide  solid  evidence  that 
dietary  polydextrose  diminishes  the  clinical  signs  in 
dogs  with  osteoarthritis,  but  a  beneficial  effect  of 
clinical  relevance  is  acceptable.  Polydextrose  at  a 
dietary inclusion level of 3% is safe in dogs (Burdock 
and Flamm, 1999). Polydextrose is heat stable and can 
be added to dog food prior to extrusion (Cho, 2009). 
This study indicates that a dose of 3% in a dry food 
would be beneficial for dogs with osteoarthritis. 
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